Navigation Links
Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinson's Disease
Date:12/12/2007

Data Suggest Continued Improvement in Motor Function at 24 Months

SAN DIEGO, Dec. 12 /PRNewswire/ -- Ceregene, Inc. today presented long-term follow-up data from a Phase 1 clinical trial of CERE-120 in 12 patients with advanced Parkinson's disease. CERE-120 uses gene therapy to deliver the neural growth factor neurturin to the major area of neurodegeneration that occurs in the brains of Parkinson's disease patients. Long-term follow up assessments at 18 and 24 months post treatment, suggest a sustained reduction in Parkinson's symptoms. It was previously reported that an average of 36 percent (p<0.001) reduction in Parkinson's symptoms was seen 12 months after CERE-120 administration. Of the 12 subjects treated, nine had shown a clinically meaningful reduction in symptoms at 12 months, and the mean improvement of these 'responders' at 12 months was 46 percent. Today it was reported that the eight evaluable responders exhibited a persistent mean improvement in symptoms of 52 percent at their longest time of follow-up (24 months for low-dose cohort and 18 months for high-dose cohort). More specifically, there was a statistically significant improvement in the primary endpoint compared to baseline (p<0.001) defined as the reduction in Parkinson's symptoms as measured by the Unified Parkinson's Disease Rating Scale (UPDRS) motor "off" score ("motor off" meaning patients were off Parkinson's medication at evaluation time). CERE-120 continues to appear safe and well-tolerated, with no treatment-related or surgically-related serious adverse events reported for any of these patients. These data were presented today at the World Congress of Parkinson's Disease by Raymond T. Bartus, Ph.D., Ceregene's executive vice president of clinical and preclinical R&D and chief operating officer.

The Phase 1 trial was an open-label study conducted in 12 patients with advanced Parkinson's disease at two clinical trial sites -- University of California, San Francisco
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... Quebec , Nov. 28, 2014  Valeant ... (TSX: VRX) today announced that its wholly owned ... aggregate principal amount of its outstanding 6.875% Senior ... " Notes ") on December 29, 2014 and ... the Notes. Following the redemption, approximately US$500 million ...
(Date:11/28/2014)... The market for both conventional and digital ... in 2014 according to Kalorama Information.  The healthcare market ... incidence of disease are driving the market.  The finding ... X-Ray: World Market Analysis . ... can be obtained at: http://www.kaloramainformation.com/Ray-Digital-8507029/ ...
(Date:11/28/2014)... -- Alimera Sciences, Inc. (NASDAQ: ALIM ... the research, development and commercialization of prescription ophthalmic ... with Deerfield Management and certain of its affiliates ... of preferred stock to Deerfield with an aggregate ... satisfaction of certain closing conditions. Alimera has also ...
Breaking Medicine Technology:Valeant Announces Redemption of US$445.0 Million Aggregate Principal Amount of its Outstanding 6.875% Senior Notes due 2018 2Kalorama: X-Ray and Digital X-Ray Market Nears 8 Billion This Year 2Kalorama: X-Ray and Digital X-Ray Market Nears 8 Billion This Year 3Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing 2Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing 3
... in mid 2010, the National Intrepid Center of Excellence ... care of military personnel and veterans suffering from traumatic brain ... ®, an advanced magnetoencephalography (MEG) device, NICoE plans to shed ... , TBI is a leading cause of sustained impairment in ...
... Ariz., Oct. 14 When it comes to slumping ... easy to point a finger at a shrinking sales ... new data from the 2009 Leadership Skills Survey, conducted ... http://www.gottochange.com ), indicates that the root of the ...
Cached Medicine Technology:National Intrepid Center of Excellence To Combat Traumatic Brain Injury With Sophisticated Brain Mapping Technology From Elekta 2National Intrepid Center of Excellence To Combat Traumatic Brain Injury With Sophisticated Brain Mapping Technology From Elekta 3Slumps in Pharmaceutical Profitability Tied to Insufficient Management Training 2Slumps in Pharmaceutical Profitability Tied to Insufficient Management Training 3
(Date:11/28/2014)... CA (PRWEB) November 28, 2014 ... on December 2, 2014. This national movement was created ... communities by giving to local charities and causes. ... Holiday, coincides with the kickoff of the holiday shopping ... is to shopping and Cyber Monday is to online ...
(Date:11/28/2014)... Now that the holiday season is here, ... nation's leading cash-for-junk-cars companies, is improving their cash offers ... competitive and help bring a little bit more joy ... year. , Along with purchasing expensive gifts for family ... deal with large travel expenses during the holiday season. ...
(Date:11/28/2014)... 28, 2014 Novatus, a leading ... Release v5.1 which provides customers with greater reporting ... , “As we continue to evolve and ... more functionality and improved performance in response to ... for Novatus. “With the enhancements that we have ...
(Date:11/28/2014)... Wisconsin (PRWEB) November 28, 2014 Dr. ... plastic surgeons , announced the expansion of Quintessa Aesthetic ... center will be located at W307 N1497 Golf Road ... , According to Dr. Campbell, the new Delafield location ... procedures for patients, including: Botox, filler injectables ...
(Date:11/28/2014)... Dr. Paul Vitenas, one of the most awarded cosmetic ... Event for those in the area that would like to learn ... Glow will take place on December 11, 2014, from 6:00 p.m. ... of Houston at 4208 Richmond Ave. , “We want to ... come and celebrate the season with us on December 11, 2014 ...
Breaking Medicine News(10 mins):Health News:Pathways Home Health & Hospice Joins #GivingTuesday; Annual Holiday Encourages Local Charitable Giving 2Health News:Pathways Home Health & Hospice Joins #GivingTuesday; Annual Holiday Encourages Local Charitable Giving 3Health News:Rusty's Auto Salvage Increasing Their Cash Offers to Help Drivers Save Throughout the Busy Holiday Season 2Health News:Novatus Releases v5.1 with New Advanced Reporting Capabilities 2Health News:Dr. Andrew Campbell to Expand Quintessa Aesthetic Center into Delafield 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 3
... June 20 (HealthDay News) -- The U.S. Food and Drug ... safety and quality of imported drugs and food products. ... increased data sharing, was created in response to rapidly rising ... The strategy is outlined in a special report called the ...
... in the US, the largest of its kind, finds that ... The study, published in the July issue of Pediatrics ... Professor of Pediatrics at Northwestern University Feinberg School of Medicine ... affects 8 percent of children under 18 years of age, ...
... University of Leicester demonstrates that general practitioners (GPs) ... early stages of dementia resulting in both missed ... Researchers from the University of Leicester in ... Health, London, UK and the Department of General ...
... ARBOR, Mich. -- Black patients having a heart attack wait ... that will restore blood flow to their hearts, according to ... differences in care may be explained by hospital quality, rather ... more likely to go to slow hospitals than were whites, ...
... Hamilton, ON (June 20, 20122) - Women with urinary ... to develop postpartum depression as those without incontinence, according ... professor in McMaster University,s School of Nursing. Postpartum ... children in the family. According to the Canadian Mental ...
... June 20, 2011 -- After more than 100 years following ... unknown. To test the validity of present and future proposals ... necessary conditions, are recommended by Jack de la Torre, MD, ... Austin, in an article published in the Journal of ...
Cached Medicine News:Health News:FDA to Step Up Inspections of Imported Products 2Health News:Study shows high prevalence and severity of childhood food allergy in the US 2Health News:GPs missing early dementia -- new study 2Health News:Black heart attack patients wait longer for advanced treatment, University of Michigan study shows 2Health News:Urinary incontinence doubles risk of postpartum depression 2Health News:3 postulates to help identify the cause of Alzheimer's disease 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: